榮昌生物-B(9995.HK)今起招股 發行價區間為50.30-52.10港元
格隆匯10月28日丨生物製藥公司榮昌生物-B(9995.HK)於2020年10月28日-11月2日招股,公司擬發行7653.7萬股H股,公開發售佔10%,國際配售佔90%,另有15%超額配股權。發行價區間為50.30港元-52.10港元/股,預期定價日為11月2日,每手500股,入場費約26312.5港元,預期將於11月9日上市。
公司致力於發現、開發和商業化創新的、具有特色的生物藥,用於治療中國乃至全球多種醫療需求未被滿足的自身免疫、腫瘤科和眼科疾病。公司開發了擁有超過十種候選藥物的完善產品線。候選藥物中,有五種處於臨牀開發階段,正在針對17種適應症進行臨牀開發,另外還有五種以上候選藥物已提交試驗性新藥(IND)申請或處於IND申請提交籌備階段。
還值得注意的是,此次IPO由19 家全球頂級投資機構組成了超豪華基石陣容,其中包括富達國際、貝萊德、奧博資本、高瓴資本、Matthews、新加坡政府投資公司、加拿大皇家銀行資管、禮來亞洲基金、清池資本、魚鷹資本、建峖投資、維梧資本、Octagon、HUDSON BAY CAPITAL等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.